Literature DB >> 24477864

Acute hepatitis C: management in the rapidly evolving world of HCV.

Suraj A Sharma1, Jordan J Feld.   

Abstract

The acute phase of hepatitis C (HCV) infection is typically defined as the initial 6 months following exposure to the virus; however, in some individuals, the acute phase of the infection can last much longer (Orland et al. Hepatology 33:321-27, 2001). Although some patients have symptoms of acute hepatitis, most infected individuals are entirely asymptomatic. As a result, many patients are unaware of the infection until it progresses to chronic infection, and may not develop symptoms until decades later with the onset of decompensated cirrhosis or hepatocellular carcinoma (HCC). A substantial proportion (20-40%) of infected patients clear the virus during the acute phase. Interferon-based treatment is also much more likely to be successful in the acute phase of infection but is relatively poorly tolerated. Therefore, recognition of acute HCV infection is critical to prioritize those patients who do not spontaneously clear the infection for immediate therapy. However, the promise of highly effective well-tolerated all-oral therapies in development may alter the management approach. This review will focus on the epidemiology, natural history, diagnosis, and treatment of acute HCV infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477864     DOI: 10.1007/s11894-014-0371-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  84 in total

1.  IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.

Authors:  Martin Lagging; Ana I Romero; Johan Westin; Gunnar Norkrans; Amar P Dhillon; Jean-Michel Pawlotsky; Stefan Zeuzem; Michael von Wagner; Francesco Negro; Solko W Schalm; Bart L Haagmans; Carlo Ferrari; Gabriele Missale; Avidan U Neumann; Elke Verheij-Hart; Kristoffer Hellstrand
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

2.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

3.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

Review 4.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

5.  Multigene tracking of quasispecies in viral persistence and clearance of hepatitis C virus.

Authors:  Song Chen; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

6.  HCV burden of infection in Egypt: results from a nationwide survey.

Authors:  J Guerra; M Garenne; M K Mohamed; A Fontanet
Journal:  J Viral Hepat       Date:  2012-02-06       Impact factor: 3.728

7.  Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C.

Authors:  C Zavaglia; M Martinetti; E Silini; R Bottelli; C Daielli; M Asti; A Airoldi; L Salvaneschi; M U Mondelli; G Ideo
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

8.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

9.  Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum.

Authors:  O Dalgard; S Jeansson; K Skaug; N Raknerud; H Bell
Journal:  Scand J Gastroenterol       Date:  2003-08       Impact factor: 2.423

10.  Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection.

Authors:  Shuye Zhang; Karen Kodys; Kui Li; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2012-10-23       Impact factor: 22.682

View more
  4 in total

1.  Commentary on Fraser et al. (2018): Evidence base for harm reduction services-the urban-rural divide.

Authors:  Kathryn E Lancaster; Carlos D Malvestutto; William C Miller; Vivian F Go
Journal:  Addiction       Date:  2018-01       Impact factor: 6.526

Review 2.  Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis.

Authors:  Bing Zhang; Nghia H Nguyen; Brittany E Yee; Benjamin Yip; Walid S Ayoub; Glen A Lutchman; Mindie H Nguyen
Journal:  Intervirology       Date:  2015-09-25       Impact factor: 1.763

Review 3.  Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection.

Authors:  Ana Maria Ortega-Prieto; Marcus Dorner
Journal:  Vaccines (Basel)       Date:  2017-09-01

Review 4.  Present and future management of viral hepatitis.

Authors:  Rocío González Grande; Inmaculada Santaella Leiva; Susana López Ortega; Miguel Jiménez Pérez
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.